Yi Jiang
No. 300 Guangzhou Road
Nanjing, 210029, China
Nanjing, 210029, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity.
Journal: Science advances
Published: April 15, 2026
Overcoming Ferroptosis-Induced Exhaustion of NK Cells through Inhibition of the ATF3-Mediated Integrated Stress Response in Ovarian Cancer.
Journal: International journal of biological sciences
Published: February 21, 2025
YBX1 promotes homologous recombination and resistance to platinum-induced stress in ovarian cancer by recognizing m5C modification.
Journal: Cancer letters
Published: March 24, 2024
Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: February 20, 2024
Olaparib combined with CDK12-IN-3 to promote genomic instability and cell death in ovarian cancer.
Journal: International journal of biological sciences
Published: January 22, 2024
Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis.
Journal: Expert review of anticancer therapy
Published: January 04, 2024
Ore improver additions alter livestock manure compost ecosystem C:N:P stoichiometry.
Journal: Environmental research
Published: October 19, 2023
Impact of surgical approach on progress of disease by type of histology in stage IA endometrial cancer: a matched-pair analysis.
Journal: BMC surgery
Published: August 24, 2023
Derivation and validation of a nomogram based on clinical characteristics to diagnose endometriosis associated ovarian cancer preoperatively.
Journal: Journal of cancer research and clinical oncology
Published: August 23, 2023
Analysis of adverse events and quality of life in high-grade serous ovarian cancer patients with Olaparib maintenance therapy: A single-center study in China.
Journal: Medicine
Published: April 14, 2023
Bractoppin, a BRCA1 carboxy-terminal domain (BRCT) inhibitor, suppresses tumor progression in ovarian borderline tumor organoids.
Journal: Biochemical and biophysical research communications
Published: November 14, 2022
Last Updated: 09/26/2026